New pill aims to keep breast cancer at bay in thousands of women

NCT ID NCT05780567

Ongoing Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Apr 26, 2026 · Last updated Jun 18, 2026 · Updated 13 times

Summary

This study tests a new drug called TQB3616 combined with standard hormone therapy to see if it can stop breast cancer from returning in women with HR-positive, HER2-negative breast cancer. About 1,946 women who have had surgery will receive either the new drug or a placebo, plus hormone therapy. The main goal is to see how long they live without the cancer coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cancer Hospital Chinese Academy of Medical Science

Beijing, Beijing Municipality, 100021, China
Suining Central Hospital

Suining, Sichuan, 629099, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, 300020, China

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER